Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lifeloc Technologies Q3 2026 Results: Net Loss of $84.9K, Loss Narrows

Lifeloc Technologies reported a net loss of $84,931 for the third quarter of 2026, an improvement from the $263,439 loss in the prior year period, driven by a 12% increase in total revenues. For the nine months ended September 30, 2026, the company reduced its operating loss to $281,649 compared to $893,139 in 2025, while securing a $500,000 related-party term loan to bolster cash reserves.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.52.3
Gross profit1.10.9
Profit before tax-0.1-0.3
Net income-0.1-0.3
EPS (diluted, $ a share)$-0.03$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+11.7%
Gross margin43.2%
Operating margin-2.0%
Source

10-Q filed with the SEC, OTC: LCTC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lifeloc Technologies, Inc: key numbers

Share price
$3.09Close, Nov 16
Market cap
$8.51M
Shares outstanding
2.75MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lifeloc Technologies, Inc

All →
4:29 PM ET 8-K
Financial Results

Lifeloc Technologies Financial Results

Lifeloc Technologies reported Q3 2026 net revenue of $2.522 million, a 12% increase year-over-year, and a narrowed net loss of $85 thousand. The company highlighted margin improvements from price increases and continued heavy R&D investment in its SpinDetect drug analyzer platform, which is entering beta testing.

Term
Q3 2026
4:41 PM ET 8-K
Investor Presentation

Lifeloc Technologies Investor Presentation

Lifeloc Technologies announced its participation in the Lytham Partners Fall 2026 Investor Conference, featuring a virtual webcast presentation and one-on-one investor meetings. Management intends to provide a business update on its breath alcohol testing operations and the development status of its SpinDetect Analyzer for rapid drug testing.

Counterparty
Lytham Partners
Earnings call
Sep 29, 2026, 2:45 PM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.